You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Drug Formulary
About the Drug Formulary Email Drug Formulary Team

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

Filtered By:
17 Items
Cancer Type: Hematologic, Lymphoma - T-cell, Rare Diseases     
Intent: Palliative
Drugs Used:
alemtuzumab (Compassionate)
... Show more tags
Quick Link(s):
Regimen Monograph
Sep 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Drugs Used:
alemtuzumab (Compassionate),
riTUXimab (Unfunded)
... Show more tags
Quick Link(s):
Regimen Monograph
Dec 2017
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Drugs Used:
alemtuzumab (Compassionate)
... Show more tags
Quick Link(s):
Regimen Monograph
Nov 2019
Cancer Type: Hematologic, Leukemia - Acute Promyelocytic (APL)     
Intent: Curative
Drugs Used:
amsacrine,
cytarabine,
tretinoin (ATRA) (Unfunded)
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Hematologic, Leukemia - Acute Myeloid (AML)     
Intent: Curative
Drugs Used:
amsacrine,
cytarabine
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Relapsed or Refractory Multiple Myeloma
New Drug Funding Program
    Daratumumab – In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma
ODB - General Benefit
    dexamethasone
... Show more tags
Drugs Used:
bortezomib,
daratumumab,
dexamethasone
... Show more tags
Quick Link(s):
Regimen Monograph
Sep 2019
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Drugs Used:
daratumumab (Unfunded)
... Show more tags
Quick Link(s):
Regimen Monograph
Updated
Dec 2019
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Funding:
New Drug Funding Program
    Daratumumab – In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma
... Show more tags
Drugs Used:
daratumumab
... Show more tags
Quick Link(s):
Regimen Monograph
Updated
Dec 2019
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Funding:
New Drug Funding Program
    Daratumumab – In Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma
ODB - General Benefit
    dexamethasone
Exceptional Access Program
    lenalidomide - For the treatment of patients with multiple myeloma with good performance status who have received at least one prior therapy.
... Show more tags
Drugs Used:
daratumumab,
dexamethasone,
lenalidomide
... Show more tags
Quick Link(s):
Regimen Monograph
Jul 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Drugs Used:
mitoXANTRONE,
fludarabine,
cyclophosphamide,
alemtuzumab (Compassionate)
... Show more tags
Quick Link(s):
Regimen Monograph
Jun 2019
Cancer Type: Gastrointestinal, Colorectal     
Intent: Palliative
Drugs Used:
aflibercept (Unfunded),
irinotecan,
leucovorin,
fluorouracil
... Show more tags
Quick Link(s):
Regimen Monograph
Aug 2019
Cancer Type: Skin, Melanoma     
Intent: Adjuvant, Curative
Funding:
New Drug Funding Program
    Interferon - Melanoma
... Show more tags
Drugs Used:
interferon alfa-2b
... Show more tags
Quick Link(s):
Regimen Monograph
Jan 2017